
Scott B Halstead

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6136912/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Is Dengue Vaccine Protection Possible?. Clinical Infectious Diseases, 2022, 74, 156-160.	5.8	8
2	Vaccine-Associated Enhanced Viral Disease: Implications for Viral Vaccine Development. BioDrugs, 2021, 35, 505-515.	4.6	16
3	NS1, Dengue's Dagger. Journal of Infectious Diseases, 2020, 221, 857-860.	4.0	6
4	COVID-19 Vaccines: Should We Fear ADE?. Journal of Infectious Diseases, 2020, 222, 1946-1950.	4.0	55
5	Ethics of a partially effective dengue vaccine: Lessons from the Philippines. Vaccine, 2020, 38, 5572-5576.	3.8	43
6	A Step in the Right Direction. Journal of Infectious Diseases, 2020, 222, 712-714.	4.0	0
7	COVID-19 and SARS Coronavirus 2: Antibodies for the Immediate Rescue and Recovery Phase. Frontiers in Immunology, 2020, 11, 1196.	4.8	10
8	Severe dengue in travellers: pathogenesis, risk and clinical management. Journal of Travel Medicine, 2019, 26, .	3.0	86
9	Dengue infection and advances in dengue vaccines for children. The Lancet Child and Adolescent Health, 2019, 3, 734-741.	5.6	29
10	A T164S mutation in the dengue virus NS1 protein is associated with greater disease severity in mice. Science Translational Medicine, 2019, 11, .	12.4	32
11	Travelling arboviruses: A historical perspective. Travel Medicine and Infectious Disease, 2019, 31, 101471.	3.0	14
12	Japanese encephalitis vaccine for travelers: risk-benefit reconsidered. Journal of Travel Medicine, 2019, 26, .	3.0	16
13	Recent advances in understanding dengue. F1000Research, 2019, 8, 1279.	1.6	63
14	ls Dengvaxia a useful vaccine for dengue endemic areas?. BMJ: British Medical Journal, 2019, 367, 15710.	2.3	23
15	Insights from direct studies on human dengue infections. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 17-19.	7.1	13
16	Cause and consequence of loss in vaccine trust. Human Vaccines and Immunotherapeutics, 2019, 15, 628-629.	3.3	3
17	Safety issues from a Phase 3 clinical trial of a live-attenuated chimeric yellow fever tetravalent dengue vaccine. Human Vaccines and Immunotherapeutics, 2018, 14, 2158-2162.	3.3	55
18	Which Dengue Vaccine Approach Is the Most Promising, and Should We Be Concerned about Enhanced Disease after Vaccination?. Cold Spring Harbor Perspectives in Biology, 2018, 10, a030700.	5.5	37

#	Article	IF	CITATIONS
19	Dengue Vaccines. , 2018, , 241-251.e6.		2
20	Japanese Encephalitis Vaccines. , 2018, , 511-548.e12.		8
21	Nguyen Trong Lan, MD, PhD. American Journal of Tropical Medicine and Hygiene, 2018, 99, 1117-1117.	1.4	Ο
22	Zika enhancement: a reality check. Lancet Infectious Diseases, The, 2017, 17, 686-688.	9.1	11
23	Consider stopping dengvaxia administration without immunological screening. Expert Review of Vaccines, 2017, 16, 301-302.	4.4	36
24	Dengvaxia sensitizes seronegatives to vaccine enhanced disease regardless of age. Vaccine, 2017, 35, 6355-6358.	3.8	159
25	Use of the live attenuated Japanese Encephalitis vaccine SA 14–14–2 in children: A review of safety and tolerability studies. Human Vaccines and Immunotherapeutics, 2017, 13, 2222-2231.	3.3	23
26	Achieving safe, effective, and durable Zika virus vaccines: lessons from dengue. Lancet Infectious Diseases, The, 2017, 17, e378-e382.	9.1	29
27	Immune correlates of protection for dengue: State of the art and research agenda. Vaccine, 2017, 35, 4659-4669.	3.8	81
28	Biologic Evidence Required for Zika Disease Enhancement by Dengue Antibodies. Emerging Infectious Diseases, 2017, 23, 569-573.	4.3	50
29	A relevant in vitro human model for the study of Zika virus antibody-dependent enhancement. Journal of General Virology, 2017, 98, 1702-1712.	2.9	29
30	Challenges to the Design of Clinical Trials for Live-Attenuated Tetravalent Dengue Vaccines. PLoS Neglected Tropical Diseases, 2016, 10, e0004854.	3.0	16
31	Licensed Dengue Vaccine: Public Health Conundrum and Scientific Challenge. American Journal of Tropical Medicine and Hygiene, 2016, 95, 741-745.	1.4	39
32	Predictors of dengue severity. Jornal De Pediatria (Versão Em Português), 2016, 92, 429-431.	0.2	0
33	Dengue Vaccine Efficacy: Not a Zero Sum Game. Journal of Infectious Diseases, 2016, 214, 2014-2014.	4.0	11
34	Dengue vaccine and the 2016 Olympics. Lancet, The, 2016, 388, 237-238.	13.7	6
35	Predictors of dengue severity. Jornal De Pediatria, 2016, 92, 429-431.	2.0	4
36	Critique of World Health Organization Recommendation of a Dengue Vaccine. Journal of Infectious Diseases, 2016, 214, 1793-1795.	4.0	52

#	Article	IF	CITATIONS
37	Response to Hadinegoro et al Vaccine, 2016, 34, 4275.	3.8	3
38	The risks behind Dengvaxia recommendation. Lancet Infectious Diseases, The, 2016, 16, 882-883.	9.1	92
39	ls discussion of dengue vaccination for the 2016 Olympics necessary?: Authors' reply. Lancet, The, 2016, 388, 1881-1882.	13.7	1
40	Dengue infection. Nature Reviews Disease Primers, 2016, 2, 16055.	30.5	415
41	Dengue vaccines: Are they safe for travelers?. Travel Medicine and Infectious Disease, 2016, 14, 378-383.	3.0	17
42	Protective and immunological behavior of chimeric yellow fever dengue vaccine. Vaccine, 2016, 34, 1643-1647.	3.8	143
43	Epidemiology of bladder stone of children: precipitating events. Urolithiasis, 2016, 44, 101-108.	2.0	16
44	The Impact of the Newly Licensed Dengue Vaccine in Endemic Countries. PLoS Neglected Tropical Diseases, 2016, 10, e0005179.	3.0	146
45	Pathogenesis of Dengue: Dawn of a New Era. F1000Research, 2015, 4, 1353.	1.6	63
46	Comment on "Dengue virus NS1 protein activates cells via Toll-like receptor 4 and disrupts endothelial cell monolayer integrity―and "Dengue virus NS1 triggers endothelial permeability and vascular leak that is prevented by NS1 vaccination― Science Translational Medicine, 2015, 7, 318le4.	12.4	3
47	Dengue Hemorrhagic Fever at 60 Years: Early Evolution of Concepts of Causation and Treatment. Microbiology and Molecular Biology Reviews, 2015, 79, 281-291.	6.6	69
48	Pathogenic Exploitation of Fc Activity. , 2014, , 333-350.		2
49	Pathologic highlights of dengue hemorrhagic fever in 13 autopsy cases from Myanmar. Human Pathology, 2014, 45, 1221-1233.	2.0	136
50	Consultation on dengue vaccines: Progress in understanding protection, 26–28 June 2013, Rockville, Maryland. Vaccine, 2014, 32, 3115-3121.	3.8	5
51	Stumbles on the path to dengue control. Lancet Infectious Diseases, The, 2014, 14, 661-662.	9.1	6
52	Dengue Antibody-Dependent Enhancement: Knowns and Unknowns. Microbiology Spectrum, 2014, 2, .	3.0	225
53	Dengue vaccines. , 2013, , 1042-1051.		7
54	ldentifying protective dengue vaccines: Guide to mastering an empirical process. Vaccine, 2013, 31, 4501-4507.	3.8	96

#	Article	IF	CITATIONS
55	High-Avidity and Potently Neutralizing Cross-Reactive Human Monoclonal Antibodies Derived from Secondary Dengue Virus Infection. Journal of Virology, 2013, 87, 12562-12575.	3.4	92
56	Japanese encephalitis vaccines. , 2013, , 312-351.		19
57	Dengue Vascular Permeability Syndrome: What, No T Cells?. Clinical Infectious Diseases, 2013, 56, 900-901.	5.8	23
58	Secondary infection as a risk factor for dengue hemorrhagic fever/dengue shock syndrome: an historical perspective and role of antibody-dependent enhancement of infection. Archives of Virology, 2013, 158, 1445-1459.	2.1	546
59	Dengue: The Syndromic Basis to Pathogenesis Research. Inutility of the 2009 WHO Case Definition. American Journal of Tropical Medicine and Hygiene, 2013, 88, 212-215.	1.4	30
60	Call to Action for Dengue Vaccine Failure. Emerging Infectious Diseases, 2013, 19, 1335-1337.	4.3	25
61	Controlling Dengue with Vaccines in Thailand. PLoS Neglected Tropical Diseases, 2012, 6, e1876.	3.0	74
62	Controversies in dengue pathogenesis. Paediatrics and International Child Health, 2012, 32, 5-9.	1.0	67
63	Dengue vaccine development: a 75% solution?. Lancet, The, 2012, 380, 1535-1536.	13.7	105
64	Epidemiological studies on dengue virus type 3 in Playa municipality, Havana, Cuba, 2001–2002. International Journal of Infectious Diseases, 2012, 16, e198-e203.	3.3	29
65	Assessing the Potential of a Candidate Dengue Vaccine with Mathematical Modeling. PLoS Neglected Tropical Diseases, 2012, 6, e1450.	3.0	31
66	Virus Role During Intraepidemic Increase in Dengue Disease Severity. Vector-Borne and Zoonotic Diseases, 2011, 11, 675-681.	1.5	28
67	New Japanese encephalitis vaccines: alternatives to production in mouse brain. Expert Review of Vaccines, 2011, 10, 355-364.	4.4	115
68	In-Depth Analysis of the Antibody Response of Individuals Exposed to Primary Dengue Virus Infection. PLoS Neglected Tropical Diseases, 2011, 5, e1188.	3.0	184
69	Dengue Fever and Dengue Hemorrhagic Fever. , 2011, , 1147-1150.e1.		4
70	New Vaccines for Japanese Encephalitis. Current Infectious Disease Reports, 2010, 12, 174-180.	3.0	19
71	Dengue: a continuing global threat. Nature Reviews Microbiology, 2010, 8, S7-S16.	28.6	1,506
72	Japanese Encephalitis: New Options for Active Immunization. Clinical Infectious Diseases, 2010, 50, 1155-1164.	5.8	84

#	Article	IF	CITATIONS
73	How Innate Immune Mechanisms Contribute to Antibody-Enhanced Viral Infections. Vaccine Journal, 2010, 17, 1829-1835.	3.1	127
74	Intrinsic antibody-dependent enhancement of microbial infection in macrophages: disease regulation by immune complexes. Lancet Infectious Diseases, The, 2010, 10, 712-722.	9.1	334
75	Japanese Encephalitis. , 2010, , 317-333.		2
76	Evaluation of Commercially Available Anti–Dengue Virus Immunoglobulin M Tests. Emerging Infectious Diseases, 2009, 15, 436-440.	4.3	188
77	Dengue 1 Virus and Dengue Hemorrhagic Fever, French Polynesia, 2001. Emerging Infectious Diseases, 2009, 15, 1265-1270.	4.3	23
78	Antibodies Determine Virulence in Dengue. Annals of the New York Academy of Sciences, 2009, 1171, E48-56.	3.8	67
79	Assessing the prognosis of dengue-infected patients. F1000 Medicine Reports, 2009, 1, .	2.9	16
80	Dengue Virus–Mosquito Interactions. Annual Review of Entomology, 2008, 53, 273-291.	11.8	345
81	Pathogenesis: Risk Factors Prior to Infection. Tropical Medicine, 2008, , 219-256.	0.3	10
82	Japanese encephalitis vaccines. , 2008, , 311-352.		62
83	Dengue vaccines. , 2008, , 1155-1161.		4
84	Natural History of Dengue Virus (DENV)–1 and DENVâ€4 Infections: Reanalysis of Classic Studies. Journal of Infectious Diseases, 2007, 195, 1007-1013.	4.0	149
85	Dengue—The Case Definition Dilemma: A Commentary. Pediatric Infectious Disease Journal, 2007, 26, 291-292.	2.0	23
86	Single dose of SA 14-14-2 vaccine provides long-term protection against Japanese encephalitis: A case–control study in Nepalese children 5 years after immunization. Vaccine, 2007, 25, 5041-5045.	3.8	115
87	The burden of dengue infection. Lancet, The, 2007, 369, 1410-1411.	13.7	61
88	Dengue. Lancet, The, 2007, 370, 1644-1652.	13.7	1,236
89	Three commentaries on â€ [~] Corticosteroids for treating dengue shock syndrome', with introduction by EBCH editor. Evidence-Based Child Health: A Cochrane Review Journal, 2007, 2, 1080-1086.	2.0	2
90	Neutralizing Antibodies after Infection with Dengue 1 Virus. Emerging Infectious Diseases, 2007, 13, 282-286.	4.3	99

#	Article	IF	CITATIONS
91	VOLUME REPLACEMENT IN INFANTS WITH DENGUE HEMORRHAGIC FEVER/DENGUE SHOCK SYNDROME. American Journal of Tropical Medicine and Hygiene, 2006, 74, 684-691.	1.4	34
92	DENGUE HEMORRHAGIC FEVER CAUSED BY SEQUENTIAL DENGUE 1–3 VIRUS INFECTIONS OVER A LONG TIME INTERVAL: HAVANA EPIDEMIC, 2001–2002. American Journal of Tropical Medicine and Hygiene, 2006, 75, 1113-1117.	1.4	114
93	Dengue hemorrhagic Fever caused by sequential dengue 1-3 virus infections over a long time interval: Havana epidemic, 2001-2002. American Journal of Tropical Medicine and Hygiene, 2006, 75, 1113-7.	1.4	53
94	More Dengue, More Questions. Emerging Infectious Diseases, 2005, 11, 740-741.	4.3	45
95	Effect of single dose of SA 14-14-2 vaccine 1 year after immunisation in Nepalese children with Japanese encephalitis: a case-control study. Lancet, The, 2005, 366, 1375-1378.	13.7	109
96	Recombination and flavivirus vaccines: a commentary. Vaccine, 2005, 23, 2956-2958.	3.8	37
97	ASSOCIATION BETWEEN SEX, NUTRITIONAL STATUS, SEVERITY OF DENGUE HEMORRHAGIC FEVER, AND IMMUNE STATUS IN INFANTS WITH DENGUE HEMORRHAGIC FEVER. American Journal of Tropical Medicine and Hygiene, 2005, 72, 370-374.	1.4	81
98	Dengue Hemorrhagic Fever in Infants: A Study of Clinical and Cytokine Profiles. Journal of Infectious Diseases, 2004, 189, 221-232.	4.0	233
99	Cost-effectiveness of a pediatric dengue vaccine. Vaccine, 2004, 22, 1275-1280.	3.8	125
100	Neutralization and Antibody-Dependent Enhancement of Dengue Viruses. Advances in Virus Research, 2003, 60, 421-467.	2.1	617
101	BIOLOGIC PROPERTIES OF DENGUE VIRUSES FOLLOWING SERIAL PASSAGE IN PRIMARY DOG KIDNEY CELLS: STUDIES AT THE UNIVERSITY OF HAWAII. American Journal of Tropical Medicine and Hygiene, 2003, 69, 5-11.	1.4	62
102	Dengue. Current Opinion in Infectious Diseases, 2002, 15, 471-476.	3.1	124
103	Effect of dengue-1 antibodies on American dengue-2 viral infection and dengue haemorrhagic fever. Lancet, The, 2002, 360, 310-312.	13.7	148
104	The future of dengue vaccines. Lancet, The, 2002, 360, 1243-1245.	13.7	123
105	Effect of age on outcome of secondary dengue 2 infections. International Journal of Infectious Diseases, 2002, 6, 118-124.	3.3	262
106	Dengue Hemorrhagic Fever in Infants: Research Opportunities Ignored. Emerging Infectious Diseases, 2002, 8, 1474-1479.	4.3	216
107	Enhanced severity of secondary dengue-2 infections: death rates in 1981 and 1997 Cuban outbreaks. Revista Panamericana De Salud Publica/Pan American Journal of Public Health, 2002, 11, 223-227.	1.1	174
108	Efficacy of single-dose SA 14–14–2 vaccine against Japanese encephalitis: a case control study. Lancet, The, 2001, 358, 791-795.	13.7	154

#	Article	IF	CITATIONS
109	Do escape mutants explain rapid increases in dengue casefatality rates within epidemics?. Lancet, The, 2000, 355, 1902-1903.	13.7	71
110	Failure of secondary infection with American genotype dengue 2 to cause dengue haemorrhagic fever. Lancet, The, 1999, 354, 1431-1434.	13.7	260
111	RISK FACTORS IN DENGUE SHOCK SYNDROME: A PROSPECTIVE EPIDEMIOLOGIC STUDY IN RAYONG, THAILAND. American Journal of Epidemiology, 1984, 120, 653-669.	3.4	627
112	Absence of Dengue 2 Infection Enhancement in Human Sera Containing Japanese Encephalitis Antibodies. American Journal of Tropical Medicine and Hygiene, 1984, 33, 288-294.	1.4	14
113	Selection of Attenuated Dengue 4 Viruses by Serial Passage in Primary Kidney Cells. American Journal of Tropical Medicine and Hygiene, 1984, 33, 654-665.	1.4	18
114	Selection of Attenuated Dengue 4 Viruses by Serial Passage in Primary Kidney Cells. American Journal of Tropical Medicine and Hygiene, 1984, 33, 666-671.	1.4	12
115	Selection of Attenuated Dengue 4 Viruses by Serial Passage in Primary Kidney Cells. American Journal of Tropical Medicine and Hygiene, 1984, 33, 672-678.	1.4	19
116	Selection of Attenuated Dengue 4 Viruses by Serial Passage in Primary Kidney Cells. American Journal of Tropical Medicine and Hygiene, 1984, 33, 679-683.	1.4	28
117	Original Antigenic Sin in Dengue. American Journal of Tropical Medicine and Hygiene, 1983, 32, 154-156.	1.4	244
118	Comparison of P388D1 Mouse Macrophage Cell Line and Human Monocytes for Assay of Dengue-2 Infection-Enhancing Antibodies. American Journal of Tropical Medicine and Hygiene, 1983, 32, 157-163.	1.4	39
119	Cause of Primary Bladder Stone in England — A Retrospective Epidemiological Study. , 1981, , 325-328.		4
120	An explanation for enhanced virus plaque formation in chick embryo cells. Nature, 1980, 285, 504-505.	27.8	41
121	Immunological Parameters of Togavirus Disease Syndromes. , 1980, , 107-173.		78
122	Transmission of Dengue 1 and 2 Viruses in Greece in 1928 *. American Journal of Tropical Medicine and Hygiene, 1980, 29, 635-637.	1.4	51
123	Enhancement of Dengue Virus Infection in Monocytes by Flavivirus Antisera *. American Journal of Tropical Medicine and Hygiene, 1980, 29, 638-642.	1.4	134
124	Dengue Virus Replication Enhancement in Peripheral Blood Leukocytes from Immune Human Beings. Experimental Biology and Medicine, 1976, 151, 136-139.	2.4	63
125	Etiologies of the Experimental Dengues of Siler and Simmons *. American Journal of Tropical Medicine and Hygiene, 1974, 23, 974-982.	1.4	92
126	Studies on the Pathogenesis of Dengue Infection in Monkeys. II. Clinical Laboratory Responses to Heterologous Infection. Journal of Infectious Diseases, 1973, 128, 15-22.	4.0	170

#	Article	IF	CITATIONS
127	STUDIES ON THE IMMUNIZATION OF MONKEYS AGAINST DENGUE. American Journal of Tropical Medicine and Hygiene, 1973, 22, 365-374.	1.4	53
128	Rubella: Reinfection of Vaccinated and Naturally Immune Persons Exposed in an Epidemic. New England Journal of Medicine, 1970, 283, 771-778.	27.0	250
129	Dengue and Chikungunya Virus Infection in Man in Thailand, 1962–1964. American Journal of Tropical Medicine and Hygiene, 1969, 18, 1022-1033.	1.4	55
130	Dengue and Chikungunya Virus Infection in Man in Thailand, 1962–1964. American Journal of Tropical Medicine and Hygiene, 1969, 18, 954-971.	1.4	303
131	Dengue and Chikungunya Virus Infection in Man in Thailand, 1962–1964. American Journal of Tropical Medicine and Hygiene, 1969, 18, 972-983.	1.4	97
132	Dengue and Chikungunya Virus Infection in Man in Thailand, 1962–1964. American Journal of Tropical Medicine and Hygiene, 1969, 18, 984-996.	1.4	72
133	Dengue and Chikungunya Virus Infection in Man in Thailand, 1962–1964. American Journal of Tropical Medicine and Hygiene, 1969, 18, 997-1021.	1.4	196
134	Studies of Bladder Stone Disease in Thailand. American Journal of Clinical Nutrition, 1967, 20, 1320-1328.	4.7	30
135	Studies of Bladder Stone Disease in Thailand. American Journal of Clinical Nutrition, 1967, 20, 1352-1361.	4.7	27
136	Studies of Bladder Stone Disease in Thailand. American Journal of Clinical Nutrition, 1967, 20, 1329-1339.	4.7	40
137	Studies of Bladder Stone Disease in Thailand. American Journal of Clinical Nutrition, 1967, 20, 1340-1351.	4.7	35
138	Studies of Bladder Stone Disease in Thailand. American Journal of Clinical Nutrition, 1967, 20, 1312-1319.	4.7	25
139	Studies of Bladder Stone Disease in Thailand. American Journal of Clinical Nutrition, 1967, 20, 1362-1368.	4.7	33
140	Shock associated with dengue infection. Journal of Pediatrics, 1966, 68, 448-456.	1.8	93
141	Recent Epidemics of Hemorrhagic Fever in Thailand: Observations Related to Pathogenesis of a "New― Dengue Disease. American Journal of Public Health and the Nation's Health, 1965, 55, 1386-1395.	0.3	45
142	Studies of hemostasis in Thai hemorrhagic fever. Journal of Pediatrics, 1965, 66, 918-926.	1.8	31
143	In vitro Recovery of Dengue Viruses from Naturally Infected Human Beings and Arthropods. Nature, 1964, 202, 931-932.	27.8	16
144	Dengue Antibody-Dependent Enhancement: Knowns and Unknowns. , 0, , 249-271.		25